日本非小细胞肺癌中可操作的致癌驱动基因检测的患者发起的全国性调查。
Patient-Initiated Nationwide Survey on Testing for Actionable Oncogenic Drivers in Non-Small Cell Lung Cancer in Japan.
机构信息
Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan.
Japan Lung Cancer Alliance, Yokohama, Japan.
出版信息
Cancer Med. 2024 Nov;13(21):e70375. doi: 10.1002/cam4.70375.
BACKGROUND
Previous reports indicated still low implementation rates of multigene testing for advanced non-small cell lung cancer (NSCLC) in Japan.
METHODS
This is a retrospective study launched at the initiative of lung cancer patients. Patients with stage IV NSCLC from January 2019 to December 2022 were investigated for testing of 8 actionable oncogenic drivers with targeted therapies available as of 2022.
RESULTS
A total of 15,719 patients were included. Between 2019 and 2022, the percentage of patients who were not tested for any actionable oncogenic drivers remained the same, ranging from 21.5% to 33.1%. However, since late 2021, the percentage of patients tested for five or more actionable oncogenic drivers has increased. Across hospital categories and regions, the number of actionable oncogenic drivers tested was similar.
CONCLUSIONS
This patient-initiated national survey in Japan reveals the recent nationwide increase in testing rates for actionable oncogenic drivers in Advanced NSCLC.
背景
先前的报告表明，在日本，多基因检测在晚期非小细胞肺癌（NSCLC）中的实施率仍然较低。
方法
这是一项由肺癌患者发起的回顾性研究。调查了 2019 年 1 月至 2022 年 12 月期间患有 IV 期 NSCLC 的患者，对 8 种可进行靶向治疗的有作用的致癌驱动基因进行了检测。
结果
共纳入 15719 名患者。2019 年至 2022 年间，未对任何有作用的致癌驱动基因进行检测的患者比例保持不变，范围在 21.5%至 33.1%之间。然而，自 2021 年底以来，对 5 个或更多有作用的致癌驱动基因进行检测的患者比例有所增加。在不同医院类别和地区，检测的有作用的致癌驱动基因数量相似。
结论
这项在日本发起的全国性调查揭示了晚期 NSCLC 中近期有作用的致癌驱动基因检测率的全国性增长。
Zotero 插件